BioanalysisPub Date : 2026-11-15DOI: 10.1080/17576180.2026.2760120
Zahra Latifpour, Maryam Khoubnasabjafari, Vahid Jouyban-Gharamaleki, Elaheh Rahimpour, Abolghasem Jouyban
{"title":"A plasmonic nanosensor: bovine serum albumin -functionalized silver nanocrystals for morphine determination via Rayleigh light scattering technique.","authors":"Zahra Latifpour, Maryam Khoubnasabjafari, Vahid Jouyban-Gharamaleki, Elaheh Rahimpour, Abolghasem Jouyban","doi":"10.1080/17576180.2026.2760120","DOIUrl":"https://doi.org/10.1080/17576180.2026.2760120","url":null,"abstract":"<p><strong>Background: </strong>Morphine is a natural phenanthrene-derived alkaloid that alleviates moderate to severe pain by activating μ-opioid receptors, which inhibit adenylate cyclase and reduce cAMP levels. Measuring its concentrations is crucial for optimizing pain management, preventing overdose, and minimizing side effects, abuse, and addiction in clinical practice.</p><p><strong>Methodology: </strong>In this work, an optical Rayleigh light scattering (RLS) probe based on silver plasmonic nanoparticles was developed for the detection of morphine in exhaled breath condensate (EBC). Silver nanocrystals (Ag NCs) were synthesized in the presence of bovine serum albumin (BSA) as a stabilizing agent, and the experimental conditions were optimized to achieve maximal RLS response.</p><p><strong>Results: </strong>The probe exhibited a strong linear correlation between analytical response and morphine concentration across 0.02-1.6 µg/mL, with a detection limit of 0.007 µg/mL.</p><p><strong>Conclusion: </strong>Morphine determination in patients' EBC samples confirmed the analytical applicability and reproducibility of the herein-validated method. To the best of our knowledge, this is the first RLS-based system for morphine detection.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149416836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-14DOI: 10.1080/17576180.2026.2760624
Ramya Ramesh, Amit Choudhary, Shiny Thomas, Pooja S Kumar, Prashant Adole, C T Aravindakumar, Prabhu Manivannan, Prasanth Ganesan, M Jayanthi, Smita Kayal
{"title":"Targeted GC-MS profiling of 34 serum free fatty acids: analytical performance and clinical application in acute lymphoblastic leukemia.","authors":"Ramya Ramesh, Amit Choudhary, Shiny Thomas, Pooja S Kumar, Prashant Adole, C T Aravindakumar, Prabhu Manivannan, Prasanth Ganesan, M Jayanthi, Smita Kayal","doi":"10.1080/17576180.2026.2760624","DOIUrl":"https://doi.org/10.1080/17576180.2026.2760624","url":null,"abstract":"<p><strong>Background: </strong>Accurate quantification of free fatty acids (FFAs) in complex biological matrices in human serum is analytically challenging due to variations in carbon chain length, polarity, and volatility.</p><p><strong>Method: </strong>In this study, we describe a targeted GC-MS (gas chromatography mass spectrometry) method for simultaneous profiling of 34 serum FFAs (C4-C24) spanning short-, medium-, and long-chain saturated and unsaturated fatty acids and evaluate its analytical performance and clinical applicability in ALL (Acute Lymphoblastic Leukemia). A one-step Folch extraction with Meth Prep II methylation was optimized for preparation of FAMEs (fatty acid methyl esters) and compounds were detected in selected ion monitoring (SIM) mode.</p><p><strong>Results: </strong>Analytical validation showed excellent linearity across the calibration range (3.7-60 µg/mL) with coefficients of determination (R<sup>2</sup>) ranging from 0.9917 to 0.9994 across the analytes. Sub µg/mL LOD values ranged from 0.0001-0.137 µg/mL, LOQ values from 0.0003-0.457 µg/mL, and lowest calibration values from 3.3-13.85 µg/mL, corresponding to lowest calibration levels. Inter-day RSD% (precision) were ±10% across analytes, while RE% (accuracy) were within ±20%. Clinical applicability was evaluated serum samples from newly diagnosed ALL patients at baseline (<i>N</i> = 142) and post-induction chemotherapy (<i>N</i> = 123). Multivariate clustering confirmed clear separation between clinical groups.</p><p><strong>Conclusion: </strong>Overall, this fit-for-purpose GC-MS profiling supports clinical metabolomics investigations of lipid dysregulation in ALL.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-12DOI: 10.1080/17576180.2026.2758031
Kenichi Aizawa
{"title":"Reframing immunosuppressant therapeutic drug monitoring: an integrated analytical framework based on microvolume whole blood.","authors":"Kenichi Aizawa","doi":"10.1080/17576180.2026.2758031","DOIUrl":"https://doi.org/10.1080/17576180.2026.2758031","url":null,"abstract":"<p><p>Therapeutic drug monitoring (TDM) is essential for optimizing immunosuppressive therapy after solid-organ transplantation, yet monitoring often lacks coherence due to use of multiple drug-specific specimen matrices, separate analytical workflows, and disparate drug concentration ranges. I propose using microvolume whole blood as a common biological matrix in an integrated analytical framework with the intent of reframing immunosuppressant TDM. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) permits multiple immunosuppressants to be quantified from a single, microvolume, whole-blood sample, enabling analysis of drugs that differ markedly in their clinically relevant concentrations. Analyte-specific ionization strategies can accommodate these differences in a single, integrated, analytical workflow, while hematocrit-based estimation of plasma-equivalent mycophenolic acid concentrations can link whole-blood measurements to established plasma-based clinical interpretation. In this framework, microsampling is not simply a means of reducing sample volume, but a method that supports whole-blood analysis based upon fingerstick collection, simplified specimen handling, and potentially even patient-centered or remote TDM. This Perspective discusses analytical and translational implications of using microvolume whole blood for immunosuppressant monitoring. It further considers the preanalytical, analytical, and clinical validation required to move from fragmented drug-specific testing to integrated TDM.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-10DOI: 10.1080/17576180.2026.2760186
Henrik Toft-Hansen, Louise Jørgensen, Daniel Elias, Marie Frederiksen, Jan Vanggaard Andersen
{"title":"Anti-drug antibody titer may guide neutralizing antibody testing.","authors":"Henrik Toft-Hansen, Louise Jørgensen, Daniel Elias, Marie Frederiksen, Jan Vanggaard Andersen","doi":"10.1080/17576180.2026.2760186","DOIUrl":"https://doi.org/10.1080/17576180.2026.2760186","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate neutralizing antibodies (NAb) against insulin icodec and explore whether an anti-drug antibody (ADA) titer threshold can guide clinically meaningful NAb testing.</p><p><strong>Patients and methods: </strong>A cell-based insulin icodec NAb assay was developed and applied to follow-up samples collected after 6 weeks of drug wash-out from two treat-to-target trials in insulin-naïve patients with type 2 diabetes. ADA status and titers, NAb status, efficacy, and safety outcomes were evaluated.</p><p><strong>Results: </strong>Of 355 follow-up samples, 270 (76%) were ADA positive and 35 (9.9%) were NAb positive. Neither ADA nor NAb status was associated with safety or efficacy concerns. The rate of NAb positivity increased with ADA titer. A titer threshold of 200 improved reliability and interpretability and reduced the number of samples requiring NAb testing by 68%. A higher threshold would be required during active treatment because of residual drug interference.</p><p><strong>Conclusions: </strong>ADA and NAb were not associated with detrimental efficacy or safety effects. Integrating ADA titers with clinical outcomes is more informative than stand-alone <i>in-vitro</i> NAb testing. When NAb testing is required, an appropriate ADA titer threshold should guide sample selection.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov IDs NCT03751657 and NCT04795531.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-09DOI: 10.1080/17576180.2026.2758032
Weifeng Xu, Tushar Garimella, Brian Booth, N Ezgi Wood, Ola M Saad, Ang Liu, Wenkui Li, Faye Vazvaei-Smith
{"title":"Bioanalysis of antibody-drug conjugates: current practices and future directions-a workshop report.","authors":"Weifeng Xu, Tushar Garimella, Brian Booth, N Ezgi Wood, Ola M Saad, Ang Liu, Wenkui Li, Faye Vazvaei-Smith","doi":"10.1080/17576180.2026.2758032","DOIUrl":"10.1080/17576180.2026.2758032","url":null,"abstract":"<p><p>The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) convened a workshop on bioanalysis of antibody-drug conjugates (ADCs) in March 2026, in Spring House, Pennsylvania. The one-day event brought together pharmaceutical industry scientists and regulatory agency representatives to discuss bioanalytical strategies for ADC development. This report summarizes key presentations-including an industry survey on the current practices, perspectives on ADC clinical pharmacology, and regulatory considerations-along with findings from breakout sessions focused on preclinical bioanalysis, pharmacokinetic assays and modeling, and immunogenicity assessments. Workshop participants generally supported early characterization of relevant ADC-related analytes, emphasizing that analyte selection should remain risk-based and molecule-specific and that measurement strategies may be streamlined when supported by data and, when appropriate, regulatory consultation. Emerging themes included the growing use of hybrid liquid chromatography-tandem mass spectrometry (LC-MS/MS) platforms, the central role of exposure-response modeling in dose optimization and assay strategy, and risk-based approaches to immunogenicity assessment. These discussions provide a foundation for advancing ADC bioanalytical best practices and regulatory alignment in this rapidly evolving therapeutic area.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Quantification of D55, an apomorphine derivative, in mouse plasma by LC-MS/MS: method development, validation, and improved pharmacokinetics compared with apomorphine.","authors":"Kohei Nagai, Natsuka Kimura, Tamaki Ishima, Hitoshi Osaka, Kenichi Aizawa","doi":"10.1080/17576180.2026.2758047","DOIUrl":"https://doi.org/10.1080/17576180.2026.2758047","url":null,"abstract":"<p><strong>Background: </strong>Apomorphine exhibits anti-cell death activity in mitochondrial disease models, but its short elimination half-life and dopaminergic activity limit its therapeutic application. D55 is a modified apomorphine derivative with enhanced anti-cell death activity and no dopaminergic effects.</p><p><strong>Research design and methods: </strong>We established and validated a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of D55 and apomorphine in mouse plasma and characterized their pharmacokinetic profiles. Validation assessed selectivity, linearity, precision and accuracy, injection carryover, extraction recovery, matrix effects, dilution integrity, and stability. Male C57BL/6J mice (<i>n</i> = 5 per group) received a single subcutaneous dose of either compound (0.5 mg/kg), and plasma concentration-time data were analyzed by noncompartmental analysis.</p><p><strong>Results: </strong>The assay required 10 μL of plasma. For D55, intra- and inter-day precision were ≤10.3%, and accuracy ranged from 86.9% to 108.6%. For apomorphine, precision was ≤6.8%, and accuracy ranged from 99.6% to 104.0%. D55 exhibited a half-life 3.13-fold longer than that of apomorphine (78.4 vs. 24.9 min) and higher systemic exposure (AUC<sub>0</sub>-∞), with geometric mean ratios of 2.60 on a mass-concentration basis (ng·min/mL) and 2.36 on a molar-concentration basis (nM·min).</p><p><strong>Conclusions: </strong>These findings support further development of D55 as a therapeutic candidate for mitochondrial diseases.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-06DOI: 10.1080/17576180.2026.2753698
Federico Riccardi Sirtori, Robert Wheller, Jordane Biarc, Christoph Bock, Charlie Britten, Lisa Dietz, Fabrizia Fusetti, Fabian Gärtner, Benno Ingelse, Robert Nelson, Bodrul Noor, Rebecca Paterson, Jörg Pausch, Vincenzo Pucci, Marie Rossen, Leroy Schreuder, Daniel Schulz-Jander, Craig Stovold, Helena Vostiarova, Philip Timmerman
{"title":"Beyond measurement: a strategic perspective on antibody-drug conjugates bioanalysis from the European Bioanalysis Forum.","authors":"Federico Riccardi Sirtori, Robert Wheller, Jordane Biarc, Christoph Bock, Charlie Britten, Lisa Dietz, Fabrizia Fusetti, Fabian Gärtner, Benno Ingelse, Robert Nelson, Bodrul Noor, Rebecca Paterson, Jörg Pausch, Vincenzo Pucci, Marie Rossen, Leroy Schreuder, Daniel Schulz-Jander, Craig Stovold, Helena Vostiarova, Philip Timmerman","doi":"10.1080/17576180.2026.2753698","DOIUrl":"https://doi.org/10.1080/17576180.2026.2753698","url":null,"abstract":"<p><p>Antibody-drug conjugates are a highly complex therapeutic modality that challenge conventional bioanalytical paradigms. Following a multidisciplinary workshop, the European Bioanalysis Forum developed a strategic perspective on how bioanalysis should evolve to support contemporary and future antibody-drug conjugates development. Central to this perspective is the recognition that antibody-drug conjugates are heterogeneous and dynamically changing therapeutic entities whose composition can be modified <i>in vivo</i> through processes such as deconjugation, payload release, linker cleavage, biotransformation and changes in DAR distribution, requiring bioanalysis to move beyond individual analyte measurements toward integrated biological understanding. The European Bioanalysis Forum proposes that bioanalytical strategies should be driven by clearly defined scientific questions and Context of Use, substantiated with additional complementary analytical approaches selected to generate evidence that supports development decisions. Rather than providing prescriptive methodological recommendations, this paper presents a flexible scientific framework that integrates multidisciplinary expertise and encourages continued scientific dialogue and publication of case studies to strengthen the evidence base as antibody-drug conjugates science continues to evolve.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-6"},"PeriodicalIF":2.1,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-05DOI: 10.1080/17576180.2026.2758539
Gabriele Sabbioni
{"title":"Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma.","authors":"Gabriele Sabbioni","doi":"10.1080/17576180.2026.2758539","DOIUrl":"10.1080/17576180.2026.2758539","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, with KRASG12D mutations present in approximately 40-45% of cases. Emerging RAS(ON) inhibitors, including RMC-6236, RMC-9805, RMC-7977, and MRTX1133, offer a promising precision medicine alternative to nonspecific chemotherapy. However, except for MRTX1133, published methods for quantifying these compounds in human plasma or blood remain unavailable.</p><p><strong>Methods: </strong>We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of RMC-6236, RMC-9805, RMC-7977, and MRTX1133 in human plasma. Plasma proteins were precipitated with ethanol using reserpine, verapamil, and labetalol as internal standards. Before LC-MS/MS analysis, 4,4'-methylenebis(2,6-diethylaniline) was added as a volumetric standard. Volumetric and internal-standard quantification produced comparable results. Due to matrix effects, analytes should be quantified using calibration curves prepared in spiked plasma.</p><p><strong>Results: </strong>The method showed excellent linearity, with r<sup>2</sup> > 0.991, across 0.1-50 ng per 0.1 mL plasma. The lower limit of quantification from spiked plasma (0.1 mL) was 0.1 ng for RMC-6236, RMC-9805, and RMC-7977, and 0.02 ng for MRTX1133.</p><p><strong>Conclusions: </strong>This first simultaneous assay for multiple KRASG12D inhibitors in human plasma supports pharmacokinetic studies and biomarker-driven PDAC clinical trials.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-03DOI: 10.1080/17576180.2026.2758060
Nadeem Ul Hassan Khan, Ahsan Rathore, Waheed Muhammad Imran, Nauman Mazhar, Shahid Nazir, Anam Munawar, Rahat Abdul Rehman, Allah Rakha
{"title":"Human seminal fluid as a novel Forensic matrix for flualprazolam and α-hydroxy flualprazolam: development and validation of a sensitive SPE-UHPLC-MS/MS method and application to real samples.","authors":"Nadeem Ul Hassan Khan, Ahsan Rathore, Waheed Muhammad Imran, Nauman Mazhar, Shahid Nazir, Anam Munawar, Rahat Abdul Rehman, Allah Rakha","doi":"10.1080/17576180.2026.2758060","DOIUrl":"https://doi.org/10.1080/17576180.2026.2758060","url":null,"abstract":"<p><strong>Aims: </strong>Flualprazolam is a novel designer benzodiazepine frequently reported in drug-facilitated sexual assaults, yet validated methods for its quantification in human seminal fluid remain limited. A sensitive method was therefore developed and validated for quantification of flualprazolam and α-hydroxy flualprazolam in human seminal fluid.</p><p><strong>Materials and methods: </strong>An ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed using solid-phase extraction, a phenyl-hexyl reversed-phase column, positive electrospray ionization and multiple reaction monitoring. Results: The method showed linearity over 0.5-200 ng/mL (R<sup>2</sup> ≥ 0.99). Limits of detection (LOD) and lower limits of quantification (LLOQ) were 0.250 and 0.500 ng/mL, respectively. Accuracy and precision were within ±20%, with extraction recovery >81%. The method was applied to 100 seminal-fluid samples.</p><p><strong>Conclusions: </strong>The validated method enables sensitive quantification of flualprazolam and α-hydroxy flualprazolam in human seminal fluid for forensic toxicological applications.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-14"},"PeriodicalIF":2.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BioanalysisPub Date : 2026-11-03DOI: 10.1080/17576180.2026.2753978
Jason Truesdale, Michael Mulvana, Stephen Lowes, Christopher Dishinger
{"title":"The simultaneous detection of multidomain ADAs using a multiplex assay optional subtitle: a multiplexed approach to multidomain ADA detection.","authors":"Jason Truesdale, Michael Mulvana, Stephen Lowes, Christopher Dishinger","doi":"10.1080/17576180.2026.2753978","DOIUrl":"https://doi.org/10.1080/17576180.2026.2753978","url":null,"abstract":"<p><strong>Background: </strong>The increasing prevalence of bispecific and multidomain therapeutics has introduced significant challenges for immunogenicity assessment, as conventional approaches rely on separate anti-drug antibody (ADA) assays for each therapeutic domain. This paradigm increases sample consumption, extends development timelines, adds operational complexity, and complicates cross-domain data interpretation.</p><p><strong>Methods: </strong>Here, we describe the development and prevalidation performance of a multiplexed, domain-specific immunogenicity assay based on Luminex<sup>Ⓡ</sup> xMAP<sup>Ⓡ</sup> technology. Pegylated Cas9 was selected as a multidomain model construct because it combines a highly immunogenic protein domain with a polymer moiety known to elicit immune responses in human populations, providing a clinically relevant test case for multiplex ADA detection.</p><p><strong>Results: </strong>The assay enables simultaneous detection of ADAs directed against multiple domains within a single workflow. Key features include on-demand biotin-avidin bead coupling, adjustable bead ratios to accommodate differing minimum required dilutions (MRDs), and assay sensitivity consistent with regulatory expectations.</p><p><strong>Conclusion: </strong>Collectively, these results demonstrate the feasibility of a unified multiplexed platform for clinical immunogenicity assessment of multidomain therapeutics, enabling domain-specific ADA characterization while reducing assay burden and sample requirements.</p>","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}